+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Gene Therapy Market Research Report by Type, Vector Type, Application, Country - North America Forecast to 2027 - Cumulative Impact of COVID-19

  • PDF Icon

    Report

  • 155 Pages
  • October 2022
  • Region: North America
  • 360iResearch™
  • ID: 5667144
UP TO OFF until Mar 31st 2023
The North America Gene Therapy Market size was estimated at USD 922.42 million in 2021, USD 1,104.70 million in 2022, and is projected to grow at a CAGR of 23.88% to reach USD 3,333.91 million by 2027.

Market Statistics:

The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Gene Therapy to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Type, the market was studied across Antigen Gene Therapy, Cancer Gene Therapy, Cytokine Gene Therapy, Suicide Gene Therapy, and Tumor Suppressor Gene Therapy.
  • Based on Vector Type, the market was studied across Non-viral Vectors and Viral Vectors.
  • Based on Application, the market was studied across Cardiovascular Diseases, Genetic Diseases, Infectious Diseases, Neurological Diseases, and Oncological Disorders.
  • Based on Country, the market was studied across Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. The ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:

The publisher continuously monitors and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Gene Therapy market considering the current update on the conflict and its global response.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Gene Therapy Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor's strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the North America Gene Therapy Market, including Abeona Therapeutics Inc., Adaptimmune Therapeutics PLC, AGC Biologics., Alnylam Pharmaceuticals, Inc., Amgen Inc., AnGes, Inc., Applied Genetic Technologies Corporation, Astellas Gene Therapies, Biogen Inc., Bluebird Bio, Inc., Editas Medicine, Inc., Human Stem Cells Institute, Ionis Pharmaceuticals, Inc., Merck & Co., Inc., Novartis AG, Orchard Therapeutics PLC, Poseida Therapeutics, Inc., Sangamo Therapeutics, Inc., Sarepta Therapeutics, Inc., Shenzhen SiBiono GeneTech Co. Ltd., and Spark Therapeutics, Inc..

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the North America Gene Therapy Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the North America Gene Therapy Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the North America Gene Therapy Market?
4. What is the competitive strategic window for opportunities in the North America Gene Therapy Market?
5. What are the technology trends and regulatory frameworks in the North America Gene Therapy Market?
6. What is the market share of the leading vendors in the North America Gene Therapy Market?
7. What modes and strategic moves are considered suitable for entering the North America Gene Therapy Market?


This product will be delivered within 2 business days.
Frequently Asked Questions about the North American Gene Therapy Market

What is the estimated value of the North American Gene Therapy Market?

The North American Gene Therapy Market was estimated to be valued at $922.42 Million in 2021.

What is the growth rate of the North American Gene Therapy Market?

The growth rate of the North American Gene Therapy Market is 23.8%, with an estimated value of $3333.91 Million by 2027.

What is the forecasted size of the North American Gene Therapy Market?

The North American Gene Therapy Market is estimated to be worth $3333.91 Million by 2027.

Who are the key companies in the North American Gene Therapy Market?

Key companies in the North American Gene Therapy Market include Abeona Therapeutics Inc., Adaptimmune Therapeutics PLC, AGC Biologics., Alnylam Pharmaceuticals, Inc., Amgen Inc., AnGes, Inc., Applied Genetic Technologies Corporation, Astellas Gene Therapies and Bluebird Bio, Inc..

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges
5.2. Cumulative Impact of COVID-19
6. Gene Therapy Market, by Type
6.1. Introduction
6.2. Antigen Gene Therapy
6.3. Cancer Gene Therapy
6.4. Cytokine Gene Therapy
6.5. Suicide Gene Therapy
6.6. Tumor Suppressor Gene Therapy
7. Gene Therapy Market, by Vector Type
7.1. Introduction
7.2. Non-viral Vectors
7.3. Viral Vectors
8. Gene Therapy Market, by Application
8.1. Introduction
8.2. Cardiovascular Diseases
8.3. Genetic Diseases
8.4. Infectious Diseases
8.5. Neurological Diseases
8.6. Oncological Disorders
9. Canada Gene Therapy Market
9.1. Introduction
10. Mexico Gene Therapy Market
10.1. Introduction
11. United States Gene Therapy Market
11.1. Introduction
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. Abeona Therapeutics Inc.
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. Adaptimmune Therapeutics PLC
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. AGC Biologics.
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. Alnylam Pharmaceuticals, Inc.
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. Amgen Inc.
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. AnGes, Inc.
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. Applied Genetic Technologies Corporation
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. Astellas Gene Therapies
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. Biogen Inc.
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. Bluebird Bio, Inc.
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. Editas Medicine, Inc.
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. Human Stem Cells Institute
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. Ionis Pharmaceuticals, Inc.
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. Merck & Co., Inc.
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. Novartis AG
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
13.16. Orchard Therapeutics PLC
13.16.1. Business Overview
13.16.2. Key Executives
13.16.3. Product & Services
13.17. Poseida Therapeutics, Inc.
13.17.1. Business Overview
13.17.2. Key Executives
13.17.3. Product & Services
13.18. Sangamo Therapeutics, Inc.
13.18.1. Business Overview
13.18.2. Key Executives
13.18.3. Product & Services
13.19. Sarepta Therapeutics, Inc.
13.19.1. Business Overview
13.19.2. Key Executives
13.19.3. Product & Services
13.20. Shenzhen SiBiono GeneTech Co. Ltd.
13.20.1. Business Overview
13.20.2. Key Executives
13.20.3. Product & Services
13.21. Spark Therapeutics, Inc.
13.21.1. Business Overview
13.21.2. Key Executives
13.21.3. Product & Services
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
List of Figures
FIGURE 1. NORTH AMERICA GENE THERAPY MARKET: RESEARCH PROCESS
FIGURE 2. NORTH AMERICA GENE THERAPY MARKET SIZE, 2021 VS 2027
FIGURE 3. NORTH AMERICA GENE THERAPY MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 4. NORTH AMERICA GENE THERAPY MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 5. NORTH AMERICA GENE THERAPY MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD MILLION)
FIGURE 6. NORTH AMERICA GENE THERAPY MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2027
FIGURE 7. NORTH AMERICA GENE THERAPY MARKET DYNAMICS
FIGURE 8. NORTH AMERICA GENE THERAPY MARKET SIZE, BY TYPE, 2021 VS 2027 (%)
FIGURE 9. NORTH AMERICA GENE THERAPY MARKET SIZE, BY TYPE, 2021 VS 2027 (USD MILLION)
FIGURE 10. NORTH AMERICA GENE THERAPY MARKET COMPETITIVE STRATEGIC WINDOW, BY TYPE, 2027
FIGURE 11. NORTH AMERICA GENE THERAPY MARKET SIZE, BY ANTIGEN GENE THERAPY, 2018-2027 (USD MILLION)
FIGURE 12. NORTH AMERICA GENE THERAPY MARKET SIZE, BY CANCER GENE THERAPY, 2018-2027 (USD MILLION)
FIGURE 13. NORTH AMERICA GENE THERAPY MARKET SIZE, BY CYTOKINE GENE THERAPY, 2018-2027 (USD MILLION)
FIGURE 14. NORTH AMERICA GENE THERAPY MARKET SIZE, BY SUICIDE GENE THERAPY, 2018-2027 (USD MILLION)
FIGURE 15. NORTH AMERICA GENE THERAPY MARKET SIZE, BY TUMOR SUPPRESSOR GENE THERAPY, 2018-2027 (USD MILLION)
FIGURE 16. NORTH AMERICA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2021 VS 2027 (%)
FIGURE 17. NORTH AMERICA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2021 VS 2027 (USD MILLION)
FIGURE 18. NORTH AMERICA GENE THERAPY MARKET COMPETITIVE STRATEGIC WINDOW, BY VECTOR TYPE, 2027
FIGURE 19. NORTH AMERICA GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2027 (USD MILLION)
FIGURE 20. NORTH AMERICA GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2027 (USD MILLION)
FIGURE 21. NORTH AMERICA GENE THERAPY MARKET SIZE, BY APPLICATION, 2021 VS 2027 (%)
FIGURE 22. NORTH AMERICA GENE THERAPY MARKET SIZE, BY APPLICATION, 2021 VS 2027 (USD MILLION)
FIGURE 23. NORTH AMERICA GENE THERAPY MARKET COMPETITIVE STRATEGIC WINDOW, BY APPLICATION, 2027
FIGURE 24. NORTH AMERICA GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2027 (USD MILLION)
FIGURE 25. NORTH AMERICA GENE THERAPY MARKET SIZE, BY GENETIC DISEASES, 2018-2027 (USD MILLION)
FIGURE 26. NORTH AMERICA GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2027 (USD MILLION)
FIGURE 27. NORTH AMERICA GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISEASES, 2018-2027 (USD MILLION)
FIGURE 28. NORTH AMERICA GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2027 (USD MILLION)
FIGURE 29. CANADA GENE THERAPY MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 30. MEXICO GENE THERAPY MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 31. UNITED STATES GENE THERAPY MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 32. UNITED STATES GENE THERAPY MARKET SIZE, BY STATE, 2021 VS 2027 (%)
FIGURE 33. UNITED STATES GENE THERAPY MARKET SIZE, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 34. UNITED STATES GENE THERAPY MARKET COMPETITIVE STRATEGIC WINDOW, BY STATE, 2027
FIGURE 35. NORTH AMERICA GENE THERAPY MARKET: FPNV POSITIONING MATRIX, 2021
FIGURE 36. NORTH AMERICA GENE THERAPY MARKET SHARE, BY KEY PLAYER, 2021
FIGURE 37. NORTH AMERICA GENE THERAPY MARKET COMPETITIVE SCENARIO, BY KEY TYPE, 2021
List of Tables
TABLE 1. NORTH AMERICA GENE THERAPY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2021
TABLE 3. NORTH AMERICA GENE THERAPY MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 4. NORTH AMERICA GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2027 (USD MILLION)
TABLE 5. NORTH AMERICA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 6. NORTH AMERICA GENE THERAPY MARKET SIZE, BY ANTIGEN GENE THERAPY, 2018-2027 (USD MILLION)
TABLE 7. NORTH AMERICA GENE THERAPY MARKET SIZE, BY ANTIGEN GENE THERAPY, BY COUNTRY, 2018-2027 (USD MILLION)
TABLE 8. NORTH AMERICA GENE THERAPY MARKET SIZE, BY CANCER GENE THERAPY, 2018-2027 (USD MILLION)
TABLE 9. NORTH AMERICA GENE THERAPY MARKET SIZE, BY CANCER GENE THERAPY, BY COUNTRY, 2018-2027 (USD MILLION)
TABLE 10. NORTH AMERICA GENE THERAPY MARKET SIZE, BY CYTOKINE GENE THERAPY, 2018-2027 (USD MILLION)
TABLE 11. NORTH AMERICA GENE THERAPY MARKET SIZE, BY CYTOKINE GENE THERAPY, BY COUNTRY, 2018-2027 (USD MILLION)
TABLE 12. NORTH AMERICA GENE THERAPY MARKET SIZE, BY SUICIDE GENE THERAPY, 2018-2027 (USD MILLION)
TABLE 13. NORTH AMERICA GENE THERAPY MARKET SIZE, BY SUICIDE GENE THERAPY, BY COUNTRY, 2018-2027 (USD MILLION)
TABLE 14. NORTH AMERICA GENE THERAPY MARKET SIZE, BY TUMOR SUPPRESSOR GENE THERAPY, 2018-2027 (USD MILLION)
TABLE 15. NORTH AMERICA GENE THERAPY MARKET SIZE, BY TUMOR SUPPRESSOR GENE THERAPY, BY COUNTRY, 2018-2027 (USD MILLION)
TABLE 16. NORTH AMERICA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2027 (USD MILLION)
TABLE 17. NORTH AMERICA GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2027 (USD MILLION)
TABLE 18. NORTH AMERICA GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, BY COUNTRY, 2018-2027 (USD MILLION)
TABLE 19. NORTH AMERICA GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2027 (USD MILLION)
TABLE 20. NORTH AMERICA GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, BY COUNTRY, 2018-2027 (USD MILLION)
TABLE 21. NORTH AMERICA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 22. NORTH AMERICA GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2027 (USD MILLION)
TABLE 23. NORTH AMERICA GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2027 (USD MILLION)
TABLE 24. NORTH AMERICA GENE THERAPY MARKET SIZE, BY GENETIC DISEASES, 2018-2027 (USD MILLION)
TABLE 25. NORTH AMERICA GENE THERAPY MARKET SIZE, BY GENETIC DISEASES, BY COUNTRY, 2018-2027 (USD MILLION)
TABLE 26. NORTH AMERICA GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2027 (USD MILLION)
TABLE 27. NORTH AMERICA GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2027 (USD MILLION)
TABLE 28. NORTH AMERICA GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISEASES, 2018-2027 (USD MILLION)
TABLE 29. NORTH AMERICA GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISEASES, BY COUNTRY, 2018-2027 (USD MILLION)
TABLE 30. NORTH AMERICA GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2027 (USD MILLION)
TABLE 31. NORTH AMERICA GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY COUNTRY, 2018-2027 (USD MILLION)
TABLE 32. CANADA GENE THERAPY MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 33. CANADA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 34. CANADA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2027 (USD MILLION)
TABLE 35. CANADA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 36. MEXICO GENE THERAPY MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 37. MEXICO GENE THERAPY MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 38. MEXICO GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2027 (USD MILLION)
TABLE 39. MEXICO GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 40. UNITED STATES GENE THERAPY MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 41. UNITED STATES GENE THERAPY MARKET SIZE, BY STATE, 2018-2027 (USD MILLION)
TABLE 42. UNITED STATES GENE THERAPY MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 43. UNITED STATES GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2027 (USD MILLION)
TABLE 44. UNITED STATES GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 45. NORTH AMERICA GENE THERAPY MARKET: FPNV POSITIONING MATRIX - SCORES, 2021
TABLE 46. NORTH AMERICA GENE THERAPY MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2021
TABLE 47. NORTH AMERICA GENE THERAPY MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2021
TABLE 48. NORTH AMERICA GENE THERAPY MARKET RANKING, BY KEY PLAYER, 2021
TABLE 49. NORTH AMERICA GENE THERAPY MARKET SHARE, BY KEY PLAYER, 2021
TABLE 50. NORTH AMERICA GENE THERAPY MARKET MERGER & ACQUISITION
TABLE 51. NORTH AMERICA GENE THERAPY MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 52. NORTH AMERICA GENE THERAPY MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 53. NORTH AMERICA GENE THERAPY MARKET INVESTMENT & FUNDING
TABLE 54. NORTH AMERICA GENE THERAPY MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 55. NORTH AMERICA GENE THERAPY MARKET: LICENSE & PRICING

Companies Mentioned

  • Abeona Therapeutics Inc.
  • Adaptimmune Therapeutics PLC
  • AGC Biologics.
  • Alnylam Pharmaceuticals, Inc.
  • Amgen Inc.
  • AnGes, Inc.
  • Applied Genetic Technologies Corporation
  • Astellas Gene Therapies
  • Biogen Inc.
  • Bluebird Bio, Inc.
  • Editas Medicine, Inc.
  • Human Stem Cells Institute
  • Ionis Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Orchard Therapeutics PLC
  • Poseida Therapeutics, Inc.
  • Sangamo Therapeutics, Inc.
  • Sarepta Therapeutics, Inc.
  • Shenzhen SiBiono GeneTech Co. Ltd.
  • Spark Therapeutics, Inc.

Methodology

Loading
LOADING...